139 related articles for article (PubMed ID: 23319569)
1. Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy.
Hsieh YT; Gang EJ; Geng H; Park E; Huantes S; Chudziak D; Dauber K; Schaefer P; Scharman C; Shimada H; Shojaee S; Klemm L; Parameswaran R; Loh M; Kang ES; Koo HH; Hofmann WK; Andrade J; Crooks GM; Willman CL; Müschen M; Papayannopoulou T; Heisterkamp N; Bönig H; Kim YM
Blood; 2013 Mar; 121(10):1814-8. PubMed ID: 23319569
[TBL] [Abstract][Full Text] [Related]
2. Overcoming Microenvironment-Mediated Chemoprotection through Stromal Galectin-3 Inhibition in Acute Lymphoblastic Leukemia.
Tarighat SS; Fei F; Joo EJ; Abdel-Azim H; Yang L; Geng H; Bum-Erdene K; Grice ID; von Itzstein M; Blanchard H; Heisterkamp N
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830047
[TBL] [Abstract][Full Text] [Related]
3. Characterizing the Motility of Chemotherapeutics-Treated Acute Lymphoblastic Leukemia Cells by Time-Lapse Imaging.
Liu HC; Gang EJ; Kim HN; Ruan Y; Ogana H; Wan Z; Bönig H; Shung KK; Kim YM
Cells; 2020 Jun; 9(6):. PubMed ID: 32560076
[TBL] [Abstract][Full Text] [Related]
4. Stromal cell-mediated mitochondrial redox adaptation regulates drug resistance in childhood acute lymphoblastic leukemia.
Liu J; Masurekar A; Johnson S; Chakraborty S; Griffiths J; Smith D; Alexander S; Dempsey C; Parker C; Harrison S; Li Y; Miller C; Di Y; Ghosh Z; Krishnan S; Saha V
Oncotarget; 2015 Dec; 6(40):43048-64. PubMed ID: 26474278
[TBL] [Abstract][Full Text] [Related]
5. Construction and characterization of human embryonic kidney-(HEK)-293T cell overexpressing truncated α4 integrin.
Fatahi A; Rahimmanesh I; Mirian M; Rohani F; Boshtam M; Gheibi A; Shariati L; Khanahmad H; Kouhpayeh S
Res Pharm Sci; 2018 Aug; 13(4):353-359. PubMed ID: 30065768
[TBL] [Abstract][Full Text] [Related]
6. Role of integrin alpha4 in drug resistance of leukemia.
Shishido S; Bönig H; Kim YM
Front Oncol; 2014; 4():99. PubMed ID: 24904821
[TBL] [Abstract][Full Text] [Related]
7. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia.
Chen Z; Shojaee S; Buchner M; Geng H; Lee JW; Klemm L; Titz B; Graeber TG; Park E; Tan YX; Satterthwaite A; Paietta E; Hunger SP; Willman CL; Melnick A; Loh ML; Jung JU; Coligan JE; Bolland S; Mak TW; Limnander A; Jumaa H; Reth M; Weiss A; Lowell CA; Müschen M
Nature; 2015 May; 521(7552):357-61. PubMed ID: 25799995
[TBL] [Abstract][Full Text] [Related]
8. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia.
Geng H; Hurtz C; Lenz KB; Chen Z; Baumjohann D; Thompson S; Goloviznina NA; Chen WY; Huan J; LaTocha D; Ballabio E; Xiao G; Lee JW; Deucher A; Qi Z; Park E; Huang C; Nahar R; Kweon SM; Shojaee S; Chan LN; Yu J; Kornblau SM; Bijl JJ; Ye BH; Ansel KM; Paietta E; Melnick A; Hunger SP; Kurre P; Tyner JW; Loh ML; Roeder RG; Druker BJ; Burger JA; Milne TA; Chang BH; Müschen M
Cancer Cell; 2015 Mar; 27(3):409-25. PubMed ID: 25759025
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia.
Swaminathan S; Klemm L; Park E; Papaemmanuil E; Ford A; Kweon SM; Trageser D; Hasselfeld B; Henke N; Mooster J; Geng H; Schwarz K; Kogan SC; Casellas R; Schatz DG; Lieber MR; Greaves MF; Müschen M
Nat Immunol; 2015 Jul; 16(7):766-774. PubMed ID: 25985233
[TBL] [Abstract][Full Text] [Related]
10. Effects of the small-molecule inhibitor of integrin α4, TBC3486, on pre-B-ALL cells.
Hsieh YT; Gang EJ; Shishido SN; Kim HN; Pham J; Khazal S; Osborne A; Esguerra ZA; Kwok E; Jang J; Bonig H; Biediger RJ; Vanderslice P; Kim YM
Leukemia; 2014 Oct; 28(10):2101-4. PubMed ID: 24903479
[No Abstract] [Full Text] [Related]
11. Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia.
Buchner M; Park E; Geng H; Klemm L; Flach J; Passegué E; Schjerven H; Melnick A; Paietta E; Kopanja D; Raychaudhuri P; Müschen M
Nat Commun; 2015 Mar; 6():6471. PubMed ID: 25753524
[TBL] [Abstract][Full Text] [Related]
12. Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance.
Jacamo R; Chen Y; Wang Z; Ma W; Zhang M; Spaeth EL; Wang Y; Battula VL; Mak PY; Schallmoser K; Ruvolo P; Schober WD; Shpall EJ; Nguyen MH; Strunk D; Bueso-Ramos CE; Konoplev S; Davis RE; Konopleva M; Andreeff M
Blood; 2014 Apr; 123(17):2691-702. PubMed ID: 24599548
[TBL] [Abstract][Full Text] [Related]
13. Ph+ ALL: drawing strength from a benign past.
Müschen M
Blood; 2015 May; 125(19):2879-80. PubMed ID: 25953975
[TBL] [Abstract][Full Text] [Related]
14. The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia.
Eswaran J; Sinclair P; Heidenreich O; Irving J; Russell LJ; Hall A; Calado DP; Harrison CJ; Vormoor J
Leukemia; 2015 Aug; 29(8):1623-31. PubMed ID: 25943180
[TBL] [Abstract][Full Text] [Related]
15. Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia.
Müschen M
Blood; 2015 Jun; 125(24):3688-93. PubMed ID: 25878119
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-15 enhances cellular proliferation and upregulates CNS homing molecules in pre-B acute lymphoblastic leukemia.
Williams MT; Yousafzai Y; Cox C; Blair A; Carmody R; Sai S; Chapman KE; McAndrew R; Thomas A; Spence A; Gibson B; Graham GJ; Halsey C
Blood; 2014 May; 123(20):3116-27. PubMed ID: 24700781
[TBL] [Abstract][Full Text] [Related]
17. RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia.
Papaemmanuil E; Rapado I; Li Y; Potter NE; Wedge DC; Tubio J; Alexandrov LB; Van Loo P; Cooke SL; Marshall J; Martincorena I; Hinton J; Gundem G; van Delft FW; Nik-Zainal S; Jones DR; Ramakrishna M; Titley I; Stebbings L; Leroy C; Menzies A; Gamble J; Robinson B; Mudie L; Raine K; O'Meara S; Teague JW; Butler AP; Cazzaniga G; Biondi A; Zuna J; Kempski H; Muschen M; Ford AM; Stratton MR; Greaves M; Campbell PJ
Nat Genet; 2014 Feb; 46(2):116-25. PubMed ID: 24413735
[TBL] [Abstract][Full Text] [Related]
18. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia.
Gang EJ; Hsieh YT; Pham J; Zhao Y; Nguyen C; Huantes S; Park E; Naing K; Klemm L; Swaminathan S; Conway EM; Pelus LM; Crispino J; Mullighan CG; McMillan M; Müschen M; Kahn M; Kim YM
Oncogene; 2014 Apr; 33(17):2169-78. PubMed ID: 23728349
[TBL] [Abstract][Full Text] [Related]
19. Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia.
Gang EJ; Kim HN; Hsieh YT; Ruan Y; Ogana HA; Lee S; Pham J; Geng H; Park E; Klemm L; Willman CL; Carroll WL; Mittelman SD; Orgel E; Oberley MJ; Parekh C; Abdel-Azim H; Bhojwani D; Wayne AS; De Arcangelis A; Georges-Labouesse E; Wayner E; Bonig H; Minasyan A; Ten Hoeve J; Graeber TG; Müschen M; Heisterkamp N; Kim YM
Blood; 2020 Jul; 136(2):210-223. PubMed ID: 32219444
[TBL] [Abstract][Full Text] [Related]
20. Aberrant stem cell and developmental programs in pediatric leukemia.
Ling RE; Cross JW; Roy A
Front Cell Dev Biol; 2024; 12():1372899. PubMed ID: 38601080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
